The Quest to Repair What Multiple Sclerosis Takes Away (opens original article in a new tab)

Quantum BioPharma is advancing Lucid-MS, a potential treatment for multiple sclerosis that directly targets myelin, following successful phase 1 trials and preparing for phase 2 studies.

• Multiple sclerosis (MS) progressively damages myelin, leading to loss of physical control and no current cure.
• Quantum BioPharma is developing Lucid-MS, a drug targeting myelin directly to prevent degradation.
• Lucid-MS has completed phase 1 trials showing favorable safety and is preparing for phase 2 trials.